Kopi Af Aktivlisten 2021-06-30 Ny.Xlsm
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Blackrock UK Smaller Companies PDF Factsheet
Adventurous 31 August 2021 Life Fund SW BlackRock UK Smaller Companies Life Asset Allocation (as at 31/07/2021) This document is provided for the purpose of UK Small Cap Companies 99.8% information only. This factsheet is intended for individuals who are familiar with investment Money Market 0.2% terminology. Please contact your financial adviser if you need an explanation of the terms used. This material should not be relied upon as sufficient information to support an investment decision. The portfolio data on this factsheet is updated on a quarterly basis. Fund Aim The fund aims for long-term growth by investing in UK smaller companies which the Fund Manager considers to have above average long-term growth prospects. The fund Sector Breakdown (as at 31/07/2021) invests solely through the BlackRock UK Consumer Discretionary 27.7% Smaller Companies Unit Trust. Industrials 25.1% Basic Fund Information Financials 12.2% Fund Launch Date 19/09/2001 Technology 11.3% Fund Size £5.3m Basic Materials 5.1% Sector ABI UK Smaller Other 4.9% Companies Energy 3.8% ISIN GB0030873565 Consumer Staples 3.8% MEX ID SWMUL Health Care 3.7% SEDOL 3087356 Telecommunications 2.5% Manager Name Roland Arnold Regional Breakdown (as at 31/07/2021) Manager Since 26/03/2015 Top Ten Holdings (as at 31/07/2021) WATCHES OF SWITZERLAND 2.9% GROUP PLC IMPAX ASSET MANAGEMENT 2.4% GROUP PLC TREATT PLC 2.2% The composition of asset mix and asset allocation may change at any time and exclude cash CVS GROUP PLC 2.1% unless otherwise stated BREEDON GROUP PLC 2.0% OXFORD INSTRUMENTS PLC 1.8% INTEGRAFIN HOLDINGS PLC 1.8% AUCTION TECHNOLOGY GROUP 1.7% PLC ERGOMED PLC 1.7% LEARNING TECHNOLOGIES GROUP 1.7% PL TOTAL 20.3% Page 1 Past Performance Fund Rating Information 100% Overall Morningstar **** Rating Morningstar Analyst Rating 50% FE fundinfo Crown Rating The FE fundinfo Crown Rating relates to this fund. -
Case 15-11663-LSS Doc 212 Filed 10/12/15 Page 1 of 109 Case 15-11663-LSS Doc 212 Filed 10/12/15 Page 2 of 109
Case 15-11663-LSS Doc 212 Filed 10/12/15 Page 1 of 109 Case 15-11663-LSS Doc 212 Filed 10/12/15 Page 2 of 109 EXHIBIT A Response Genetics, Inc. - U.S. CaseMail 15-11663-LSS Doc 212 Filed 10/12/15 Page 3 of 109 Served 10/9/2015 12 WEST CAPITAL MANAGEMENT LP 1727 JFK REALTY LP 3S CORPORATION 90 PARK AVENUE, 41ST FLOOR A PARTNERSHIP 1251 E. WALNUT NEW YORK, NY 10016 1727 JFK REALTY LLC CARSON, CA 90746 100 ENGLE ST CRESSKILL, NJ 07626-2269 4281900 CANADA INC. A C PHILLIPS AAAGENT SERVICES, LLC ATTN: DEBORAH DOLMAN 2307 CRESTVIEW ST 125 LOCUST ST. 100 RUE MARIE-CURIE THE VILLAGES, FL 32162-3455 HARRISBURG, PA 17101 DOLLARD-DES-ORMEAUX, QC H9A 3C6 CANADA AARON D SUMMERS AARON K BROTEN IRA TD AMERITRADE AARON WANG 202 S SUNNY SLOPE ST CLEARING CUSTODIAN 6880 SW 44TH ST #215 W FRANKFORT, IL 62896-3104 1820 PLYMOUTH LN UNIT 2 MIAMI, FL 33155-4765 CHANHASSEN, MN 55317-4837 AASHISH WAGLE ABBOTT MOLECULAR INC. ABBOTT MOLECULAR INC. 2220 W MISSION LN APT 1222 1300 EAST TOUHY AVENUE 75 REMITTANCE DRIVE SUTIE 6809 PHOENIX, AZ 85021 DES PLAINES, IL 60068 CHICAGO, IL 60675-6809 ABBOTT MOLECULAR INC. ABDUL BASIT BUTT ABE OFFICE FURNITURE OUTLET DIVISION COUNSEL 14 RENOIR DRIVE 3400 N. PECK RD. 1350 E. TOUHY AVE., STE 300W MONMOUTH JUNCTION, NJ 08852 EL MONTE, CA 91731 DES PLAINES, IL 60018 ABEDIN JAMAL ABEY M GEORGE ABHIJIT D NAIK 9253 REGENTS RD UNIT A207 3206 LOCHAVEN DR 1049 W OGDEN AVE LA JOLLA, CA 92037-9161 ROWLETT, TX 75088 APT 103 NAPERVILLE, IL 60563 ABRAHAM BROWN ACCENT - 1 ACCENT - 2 DESIGNATED BENE PLAN/TOD P.O. -
Portfolio Holdings Listing Fidelity Advisor Asset Manager 40% As Of
Portfolio Holdings Listing Fidelity Advisor Asset Manager 40% DUMMY as of July 30, 2021 The portfolio holdings listing (listing) provides information on a fund’s investments as of the date indicated. Top 10 holdings information (top 10 holdings) is also provided for certain equity and high income funds. The listing and top 10 holdings are not part of a fund’s annual/semiannual report or Form N-Q and have not been audited. The information provided in this listing and top 10 holdings may differ from a fund’s holdings disclosed in its annual/semiannual report and Form N-Q as follows, where applicable: With certain exceptions, the listing and top 10 holdings provide information on the direct holdings of a fund as well as a fund’s pro rata share of any securities and other investments held indirectly through investment in underlying non- money market Fidelity Central Funds. A fund’s pro rata share of the underlying holdings of any investment in high income and floating rate central funds is provided at a fund’s fiscal quarter end. For certain funds, direct holdings in high income or convertible securities are presented at a fund’s fiscal quarter end and are presented collectively for other periods. For the annual/semiannual report, a fund’s investments include trades executed through the end of the last business day of the period. This listing and the top 10 holdings include trades executed through the end of the prior business day. The listing includes any investment in derivative instruments, and excludes the value of any cash collateral held for securities on loan and a fund’s net other assets. -
EP Vantage Interview - Silence Hoping to Have Something to Shout About in 2009
December 22, 2008 EP Vantage Interview - Silence hoping to have something to shout about in 2009 Lisa Urquhart With its first product expected to go into the clinic potentially as early as January, Silence Therapeutics is hoping that 2009 will be year it has something to shout about and one that will reverse the alarming share price decline that has seen the company’s valuation slip from a high of over £170m in June 2007 to £21.6m today. Silence is one of a growing number of companies working in RNA interference (RNAi) and particularly short interfering RNA (siRNA), which work by selectively silencing or inactivating genes related to certain diseases. It is importantly one of only two companies that have composition of matter patent protection for their siRNA drugs. Speaking to EP Vantage, Iain Ross, chief executive of Silence, says: “It’s a big year coming up for us.” The group has spent most of the last 12 months strengthening its IP position, and next year comes the important move of the group’s lead candidate Atu027 into the clinic, an event Mr Ross says should take place in the first quarter of the year. Many expect it could be as soon as the end of January. Partnering focus What is less expected is the speed at which Mr Ross intends to partner the drug, which is being developed in solid tumours, with an emphasis on lung cancer. “We would be looking at doing something either at the end of 2009 or the beginning of 2010,” he says. Key to partnering discussions will be the drug demonstrating good safety data in a number of cancer patients, which could be the catalyst to starting talks with big pharma who have already started to ask about Atu027. -
IQVIA Pharma Deals Half-Year Review of 2020
White Paper IQVIA Pharma Deals Half-Year Review of 2020 HEATHER CARTWRIGHT, Senior Analyst, Global Market Insights, IQVIA MICHELLE LIU, Analyst, Global Market Insights, IQVIA TASKIN AHMED, Manager, Global Market Insights, IQVIA Table of contents Introduction 1 Uncertainty and prudence cause M&A to stall 2 Licensing deal values continue to rise 5 Roche pips AstraZeneca to title of most active dealmaker 10 COVID-19 pandemic drives increase in R&D collaboration 11 Infectious diseases replace oncology as top therapeutic area for dealmaking 14 Outlook for H2 2020 15 About the authors 17 Introduction COVID-19 shakes up the dealmaking landscape H1 2020 was an unprecedented time for dealmaking in the life sciences sector. While the COVID-19 pandemic rapidly provoked a significant level of partnering activity amongst biopharma companies keen to expedite the development of vaccines or therapeutics to tackle the virus, it also acted as a brake on other types of dealmaking, most notably M&A which saw a sharp decline in activity as a result of uncertainty and operational disruption. Indeed, H1 2020 was notable for the absence of any US$5 B deals on the scale seen in previous years as companies instead focused their attentions on internal programs and potential COVID-19 solutions, opting only for a few asset-driven acquisitions. There was also plentiful capital available to allow biotech companies to stay independent, particularly those in the US. As a result, aggregate spending on M&A by life science companies plummeted to just US$19.1 B in the first 6 months of 2020. -
RETAIL BANKING Americas DIGEST
Financial Services VOLUME III – SUMMER 2013 RETAIL BANKING AMERICAS DIGEST IN THIS ISSUE 1. SMALL BUSINESS BANKING Challenging Conventional Wisdom to Achieve Outsize Growth and Profitability 2. FINANCING SMALL BUSINESSES How “New-Form Lending” Will Reshape Banks’ Small Business Strategies 3. ENHANCED PERFORMANCE MANAGEMENT Driving Breakthrough Productivity in Retail Banking Operations 4. INNOVatION IN MORtgagE OPERatIONS Building a Scalable Model 5. CHASE MERCHANT SERVICES How Will it Disrupt the Card Payments Balance of Power? 6. THE FUTURE “AR Nu” What We Can Learn from Sweden About the Future of Retail Distribution FOREWORD Banking is highly regulated, intensely competitive and provides products that, while omnipresent in consumers’ lives, are neither top-of-mind nor enticing to change. These factors drive the role and form of innovation the industry can capitalize on. In traditional business history – the realm of auto manufacturers, microchip makers, logistics companies and retailers – the literature rightly hails disruptive, game-changing innovation as the engine behind outsized profits for the first movers. In banking, such innovation is very rare. Disruptive innovations of the magnitude of the smartphone or social networking grab headlines, but are hard to leverage in the banking industry. There are simply too many restrictions on what banks can do, and too much consumer path dependency, to place all the shareholders’ chips on disruptive innovation plays. Instead, successful banks develop and execute strategies around less “flashy”, -
Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767% -
SA FUNDS INVESTMENT TRUST Form N-Q Filed 2016-11-23
SECURITIES AND EXCHANGE COMMISSION FORM N-Q Quarterly schedule of portfolio holdings of registered management investment company filed on Form N-Q Filing Date: 2016-11-23 | Period of Report: 2016-09-30 SEC Accession No. 0001206774-16-007593 (HTML Version on secdatabase.com) FILER SA FUNDS INVESTMENT TRUST Mailing Address Business Address 10 ALMADEN BLVD, 15TH 10 ALMADEN BLVD, 15TH CIK:1075065| IRS No.: 770216379 | State of Incorp.:DE | Fiscal Year End: 0630 FLOOR FLOOR Type: N-Q | Act: 40 | File No.: 811-09195 | Film No.: 162016544 SAN JOSE CA 95113 SAN JOSE CA 95113 (800) 366-7266 Copyright © 2016 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number: 811-09195 SA FUNDS - INVESTMENT TRUST (Exact name of registrant as specified in charter) 10 Almaden Blvd., 15th Floor, San Jose, CA 95113 (Address of principal executive offices) (Zip Code) Deborah Djeu Chief Compliance Officer SA Funds - Investment Trust 10 Almaden Blvd., 15th Floor, San Jose, CA 95113 (Name and Address of Agent for Service) Copies to: Brian F. Link Mark D. Perlow, Esq. Vice President and Managing Counsel Counsel to the Trust State Street Bank and Trust Company Dechert LLP 100 Summer Street One Bush Street, Suite 1600 7th Floor, Mailstop SUM 0703 San Francisco, CA 94104-4446 Boston, MA 02111 Registrants telephone number, including area code: (800) 366-7266 Date of fiscal year end: June 30 Date of reporting period: September 30, 2016 Copyright © 2013 www.secdatabase.com. -
Reduction in the Risk of Major Adverse Cardiovascular Events
Reduction in the Risk of Major Adverse Cardiovascular Events with Apabetalone, a BET Protein Inhibitor, in Patients with Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the BETonMACE Trial Gregory G. Schwartz1, Stephen J. Nicholls2, Henry N. Ginsberg3, Jan O. Johansson4, Kamyar Kalantar‐Zadeh5, Ewelina Kulikowski4, Peter P Toth6, Norman Wong4, Michael Sweeney4, Kausik K Ray7 On behalf of the BETonMACE Investigators 1Division of Cardiology, University of Colorado School of Medicine, Aurora, CO USA; 2Monash University Cardiovascular Research Center, Melbourne, Australia; 3Vagelos College of Physicians and Surgeons, Columbia University, New York, NY USA; 4Resverlogix Corp., Calgary, Alberta, Canada; 5University of California Irvine School of Medicine, Orange, CA USA; 6CGH Medical Center, Sterling, IL and Johns Hopkins University, Baltimore, MD USA; 7Imperial College Center for Cardiovascular Disease Prevention, London UK American Heart Association – 2020 Scientific Sessions November 2020 ClinicalTrials.gov: NCT02586155 Disclosures • The BETonMACE trial was funded by Resverlogix • Dr Schwartz reports research grants to the University of Colorado from Resverlogix, Sanofi, The Medicines Company, and Roche; and is coinventor of pending US patent 14/657192 (“Methods of Reducing Cardiovascular Risk”) assigned in full to the University of Colorado. • Dr. Nicholls reports grants from Resverlogix, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from -
Unlocking the Potential of Gene Silencing for Everyone
Corporate Presentation JP Morgan Conference January 2018 Forward looking statements The information contained in this presentation is being supplied and communicated to you on a Securities in the Company have not been, and will not be, registered under the United States confidential basis solely for your information and may not be reproduced, further distributed to Securities Act of 1933, as amended (the “Securities Act”), or qualified for sale under the law of any other person or published, in whole or in part, for any purpose. In accordance with the any state or other jurisdiction of the United States of America and may not be offered or sold in prohibition on market abuse contained in Part VIII of the Financial Services and Markets Act the United States of America except pursuant to an exemption from, or in a transaction not 2000 (as amended) (the “Act”): (i) you must not pass this information to any person; and (ii) subject to, the registration requirements of the Securities Act. Neither the United States you must not base any behaviour in relation to any securities or other Qualifying Investments Securities and Exchange Commission nor any securities regulatory body of any state or other (as that term is defined in the Act) which would amount to market abuse on such information jurisdiction of the United States of America, nor any securities regulatory body of any other until after it is made generally available. country or political subdivision thereof, has approved or disapproved of this presentation or the securities discussed herein or passed on the accuracy or adequacy of the contents of this This presentation is being communicated in the United Kingdom only to (a) persons who have presentation. -
GSK's Big Reveal
3 August 2018 No. 3916 Scripscrip.pharmaintelligence.informa.com Pharma intelligence | informa at Genentech Inc. (Also see “GSK Bags Bar- ron As R&D Boss As Vallance Joins UK Govern- ment” - Scrip, 8 Nov, 2017.) With a budding early immuno-oncology pipeline, Walmsley clearly has her eye on establishing GSK as an important player in the space. The event in London was Barron’s first op- portunity to present his R&D strategy and coincided with the company’s second quar- ter sales and earnings release. “This is an ideal time to be thinking about reinventing R&D, because we are doing well. We are growing,” Barron said. PILLARS FOR INNOVATION Investors have been eager to hear from the R&D legend, but with few near-term catalysts or big changes to the late-stage pipeline, they may be underwhelmed by the update. Barron, meanwhile, is focused on deliver- GSK’s Big Reveal: ing scientific and cultural changes that will yield breakthroughs over the long-term. An R&D Overhaul Poised To Yield He talked about a time horizon of 2021 to 2026, and he talked more high-level, rather than specifics, about incentives needed to Long-Term Cultural Change drive innovation, the technologies that can JESSICA MERRILL [email protected] help improve clinical trial success, and cul- tural changes. He said science, technology laxoSmithKline PLC CEO Emma pharma R&D – is that investors will need to and culture are the three pillars needed to Walmsley may have spelled out the be patient to see GSK deliver on its promise drive innovation, and all three must be in Gbig pharma’s R&D turnaround plan of innovation. -
FTSE Russell Publications
2 FTSE Russell Publications 19 August 2021 FTSE 250 Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 3i Infrastructure 0.43 UNITED Bytes Technology Group 0.23 UNITED Edinburgh Investment Trust 0.25 UNITED KINGDOM KINGDOM KINGDOM 4imprint Group 0.18 UNITED C&C Group 0.23 UNITED Edinburgh Worldwide Inv Tst 0.35 UNITED KINGDOM KINGDOM KINGDOM 888 Holdings 0.25 UNITED Cairn Energy 0.17 UNITED Electrocomponents 1.18 UNITED KINGDOM KINGDOM KINGDOM Aberforth Smaller Companies Tst 0.33 UNITED Caledonia Investments 0.25 UNITED Elementis 0.21 UNITED KINGDOM KINGDOM KINGDOM Aggreko 0.51 UNITED Capita 0.15 UNITED Energean 0.21 UNITED KINGDOM KINGDOM KINGDOM Airtel Africa 0.19 UNITED Capital & Counties Properties 0.29 UNITED Essentra 0.23 UNITED KINGDOM KINGDOM KINGDOM AJ Bell 0.31 UNITED Carnival 0.54 UNITED Euromoney Institutional Investor 0.26 UNITED KINGDOM KINGDOM KINGDOM Alliance Trust 0.77 UNITED Centamin 0.27 UNITED European Opportunities Trust 0.19 UNITED KINGDOM KINGDOM KINGDOM Allianz Technology Trust 0.31 UNITED Centrica 0.74 UNITED F&C Investment Trust 1.1 UNITED KINGDOM KINGDOM KINGDOM AO World 0.18 UNITED Chemring Group 0.2 UNITED FDM Group Holdings 0.21 UNITED KINGDOM KINGDOM KINGDOM Apax Global Alpha 0.17 UNITED Chrysalis Investments 0.33 UNITED Ferrexpo 0.3 UNITED KINGDOM KINGDOM KINGDOM Ascential 0.4 UNITED Cineworld Group 0.19 UNITED Fidelity China Special Situations 0.35 UNITED KINGDOM KINGDOM KINGDOM Ashmore